SRPT•benzinga•
A Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16%
Summary
Morgan Stanley raised the price target on Sarepta Therapeutics Inc (NASDAQ: SRPT) with an equal weight rating.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 8, 2022 by benzinga